



Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September

ANAHEIM, Calif., Aug. 24, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the following investor conferences in early September:

- The Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City. Don M. Bailey, President and Chief Executive Officer, is scheduled to provide an overview of the Company on Wednesday, September 14, 2011 at 8:00 a.m. ET. Presentations at this conference are not available by webcast.
- UBS Global Life Sciences Conference at the Grand Hyatt in New York City. Mr. Bailey is scheduled to present on Monday, September 19, 2011 at 10:30 a.m. ET. A live webcast and subsequent archived replay of the presentation will be accessible at www.questcor.com, in the "Investor Relations" section under "Events & Presentations."

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

News Provided by Acquire Media